Microbix Biosystems Inc. develops and commercializes proprietary biological and technology solutions for human health and wellbeing. Microbix manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens and pathogens used in immunoassays or quality assessment and proficiency testing products. Its annual revenues of over $10 million are largely derived from these product lines, referred to as the Antigens Business or Virology Business.
The company also applies its biological expertise to develop other innovative and proprietary technologies and products. Its development project pipeline currently includes two such proprietary products: (1) Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots, and (2) LumiSort™, a technology for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest, such as in sexing semen.